<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6686">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02090803</url>
  </required_header>
  <id_info>
    <org_study_id>2012-01</org_study_id>
    <secondary_id>2012-A000243-40</secondary_id>
    <nct_id>NCT02090803</nct_id>
  </id_info>
  <brief_title>Assessment of Human Herpes Virus Reactivation 6 Post Autologous Stem Cells</brief_title>
  <acronym>VIRAUTO6</acronym>
  <official_title>Assessment of Human Herpes Virus Reactivation 6 Post Autologous Stem Cells , Prospective, Open, Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de la Loire</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Cancérologie de la Loire</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the human herpes virus reactivation 6 post autologous
      stem cells in 196 patients. The aim of our study was to describe the incidence of
      reactivation of HHV-6 in patients requiring autologous HSCT and determine the pathogenic
      role in this target population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>HHV-6 biological reactivation</measure>
    <time_frame>40 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>HHV-6 biological reactivation (blood viral load) is defined by a detectable viral load HHV-6 and&gt; 450 copies / mL on two occasions one week apart.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aplasia output or engraftment</measure>
    <time_frame>40 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reconstitution of hematopoiesis</measure>
    <time_frame>40 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease HHV-6</measure>
    <time_frame>40 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">196</enrollment>
  <condition>Hematologic Diseases</condition>
  <arm_group>
    <arm_group_label>Graft of autologous hematopoietic stem cells</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        consecutive patient
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all patients hospitalized in the Hematology Clinic of Saint-Etienne and
             Clermont-Ferrand and receiving autologous hematopoietic stem cells, according to the
             decision of the Consultative Meeting Multidisciplinary service;

          -  Autologous recipients are included irrespective of causal hemopathy (myeloma,
             lymphoma, acute leukemia, mainly).

        Exclusion Criteria:

          -  The non-consenting patients or unable to give consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jérôme Cornillon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie Lucien Neuwirth</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jérôme Cornillon</last_name>
    <phone>04 77 91 70 60</phone>
    <email>jerome.cornillon@icloire.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques-Olivier Bay, MDPhD</last_name>
    </contact>
    <investigator>
      <last_name>Jacques-Olivier BAY, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>De Bolle L, Naesens L, De Clercq E. Update on human herpesvirus 6 biology, clinical features, and therapy. Clin Microbiol Rev. 2005 Jan;18(1):217-45. Review.</citation>
    <PMID>15653828</PMID>
  </reference>
  <reference>
    <citation>Boutolleau D, Duros C, Bonnafous P, Caïola D, Karras A, Castro ND, Ouachée M, Narcy P, Gueudin M, Agut H, Gautheret-Dejean A. Identification of human herpesvirus 6 variants A and B by primer-specific real-time PCR may help to revisit their respective role in pathology. J Clin Virol. 2006 Mar;35(3):257-63. Epub 2005 Sep 23.</citation>
    <PMID>16183328</PMID>
  </reference>
  <reference>
    <citation>Yamanishi K, Okuno T, Shiraki K, Takahashi M, Kondo T, Asano Y, Kurata T. Identification of human herpesvirus-6 as a causal agent for exanthem subitum. Lancet. 1988 May 14;1(8594):1065-7.</citation>
    <PMID>2896909</PMID>
  </reference>
  <reference>
    <citation>Santoro F, Kennedy PE, Locatelli G, Malnati MS, Berger EA, Lusso P. CD46 is a cellular receptor for human herpesvirus 6. Cell. 1999 Dec 23;99(7):817-27.</citation>
    <PMID>10619434</PMID>
  </reference>
  <reference>
    <citation>Agut H. Deciphering the clinical impact of acute human herpesvirus 6 (HHV-6) infections. J Clin Virol. 2011 Nov;52(3):164-71. doi: 10.1016/j.jcv.2011.06.008. Epub 2011 Jul 22. Review.</citation>
    <PMID>21782505</PMID>
  </reference>
  <reference>
    <citation>Ljungman P, Wang FZ, Clark DA, Emery VC, Remberger M, Ringdén O, Linde A. High levels of human herpesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patients. Br J Haematol. 2000 Dec;111(3):774-81.</citation>
    <PMID>11122137</PMID>
  </reference>
  <reference>
    <citation>Ljungman P. Immune reconstitution and viral infections after stem cell transplantation. Bone Marrow Transplant. 1998 Apr;21 Suppl 2:S72-4. Review.</citation>
    <PMID>9630332</PMID>
  </reference>
  <reference>
    <citation>Agut H. [Acute human herpesvirus 6 (HHV-6) infections: when and how to treat?]. Pathol Biol (Paris). 2011 Apr;59(2):108-12. doi: 10.1016/j.patbio.2010.07.015. Epub 2010 Sep 15. Review. French.</citation>
    <PMID>20832191</PMID>
  </reference>
  <reference>
    <citation>Kamble RT, Clark DA, Leong HN, Heslop HE, Brenner MK, Carrum G. Transmission of integrated human herpesvirus-6 in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Sep;40(6):563-6. Epub 2007 Jul 16.</citation>
    <PMID>17637686</PMID>
  </reference>
  <reference>
    <citation>Lee SO, Brown RA, Razonable RR. Clinical significance of pretransplant chromosomally integrated human herpesvirus-6 in liver transplant recipients. Transplantation. 2011 Jul 27;92(2):224-9. doi: 10.1097/TP.0b013e318222444a.</citation>
    <PMID>21629177</PMID>
  </reference>
  <reference>
    <citation>Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F, Sotto JJ, Guilhot F, Marit G, Doyen C, Jaubert J, Fuzibet JG, François S, Benboubker L, Monconduit M, Voillat L, Macro M, Berthou C, Dorvaux V, Pignon B, Rio B, Matthes T, Casassus P, Caillot D, Najman N, Grosbois B, Bataille R, Harousseau JL; Intergroupe Francophone du Myélome. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood. 2002 Feb 1;99(3):731-5.</citation>
    <PMID>11806971</PMID>
  </reference>
  <reference>
    <citation>Leong HN, Tuke PW, Tedder RS, Khanom AB, Eglin RP, Atkinson CE, Ward KN, Griffiths PD, Clark DA. The prevalence of chromosomally integrated human herpesvirus 6 genomes in the blood of UK blood donors. J Med Virol. 2007 Jan;79(1):45-51.</citation>
    <PMID>17133548</PMID>
  </reference>
  <reference>
    <citation>Ogata M. Human herpesvirus 6 in hematological malignancies. J Clin Exp Hematop. 2009 Nov;49(2):57-67. Review.</citation>
    <PMID>19907110</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 17, 2014</lastchanged_date>
  <firstreceived_date>March 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
